275 related articles for article (PubMed ID: 24857079)
1. Risk stratification for wilms tumor: current approach and future directions.
Dome JS; Perlman EJ; Graf N
Am Soc Clin Oncol Educ Book; 2014; ():215-23. PubMed ID: 24857079
[TBL] [Abstract][Full Text] [Related]
2. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
[TBL] [Abstract][Full Text] [Related]
3. New approaches to risk stratification for Wilms tumor.
Nelson MV; van den Heuvel-Eibrink MM; Graf N; Dome JS
Curr Opin Pediatr; 2021 Feb; 33(1):40-48. PubMed ID: 33394739
[TBL] [Abstract][Full Text] [Related]
4. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
[TBL] [Abstract][Full Text] [Related]
5. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
[TBL] [Abstract][Full Text] [Related]
6. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.
Fernandez CV; Perlman EJ; Mullen EA; Chi YY; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G; Kalapurakal JA; Bocking T; Huff V; Tian J; Geller JI; Grundy PE; Anderson JR; Dome JS; Shamberger RC
Ann Surg; 2017 Apr; 265(4):835-840. PubMed ID: 27811504
[TBL] [Abstract][Full Text] [Related]
8. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.
Dome JS; Graf N; Geller JI; Fernandez CV; Mullen EA; Spreafico F; Van den Heuvel-Eibrink M; Pritchard-Jones K
J Clin Oncol; 2015 Sep; 33(27):2999-3007. PubMed ID: 26304882
[TBL] [Abstract][Full Text] [Related]
9. The evolution of treatment for Wilms tumor.
Green DM
J Pediatr Surg; 2013 Jan; 48(1):14-9. PubMed ID: 23331787
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
[TBL] [Abstract][Full Text] [Related]
12. Wilms tumor.
Pater L; Melchior P; Rübe C; Cooper BT; McAleer MF; Kalapurakal JA; Paulino AC
Pediatr Blood Cancer; 2021 May; 68 Suppl 2():e28257. PubMed ID: 32893998
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
Dix DB; Fernandez CV; Chi YY; Mullen EA; Geller JI; Gratias EJ; Khanna G; Kalapurakal JA; Perlman EJ; Seibel NL; Ehrlich PF; Malogolowkin M; Anderson J; Gastier-Foster J; Shamberger RC; Kim Y; Grundy PE; Dome JS;
J Clin Oncol; 2019 Oct; 37(30):2769-2777. PubMed ID: 31449468
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.
Kinoshita Y; Suminoe A; Inada H; Yagi M; Yanai F; Zaizen Y; Nishi M; Inomata Y; Kawakami K; Matsufuji H; Suenobu S; Handa N; Kohashi K; Oda Y; Hara T; Taguchi T
J Pediatr Surg; 2012 Dec; 47(12):2205-9. PubMed ID: 23217877
[TBL] [Abstract][Full Text] [Related]
15. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
16. Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor.
Dome JS; Mullen EA; Dix DB; Gratias EJ; Ehrlich PF; Daw NC; Geller JI; Chintagumpala M; Khanna G; Kalapurakal JA; Renfro LA; Perlman EJ; Grundy PE; Fernandez CV
J Natl Compr Canc Netw; 2021 Aug; 19(8):978-985. PubMed ID: 34416705
[TBL] [Abstract][Full Text] [Related]
17. Management and outcome of pediatric metastatic Wilms' tumor at the National Cancer Institute, Egypt.
Elayadi M; Magdy S; Khalil E; Zekri W
J Egypt Natl Canc Inst; 2020 Apr; 32(1):19. PubMed ID: 32372204
[TBL] [Abstract][Full Text] [Related]
18. The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol.
Vujanić GM; Gessler M; Ooms AHAG; Collini P; Coulomb-l'Hermine A; D'Hooghe E; de Krijger RR; Perotti D; Pritchard-Jones K; Vokuhl C; van den Heuvel-Eibrink MM; Graf N;
Nat Rev Urol; 2018 Nov; 15(11):693-701. PubMed ID: 30310143
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of nuclear unrest and p53 immunostaining in Wilms' tumor.
Salama A; Kamel A
J Egypt Natl Canc Inst; 2011 Mar; 23(1):31-9. PubMed ID: 22099934
[TBL] [Abstract][Full Text] [Related]
20. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
Park JE; Noh OK; Lee Y; Choi HS; Han JW; Hahn SM; Lyu CJ; Lee JW; Yoo KH; Koo HH; Jeong SY; Sung KW
Cancer Res Treat; 2020 Apr; 52(2):438-445. PubMed ID: 31505910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]